IFL protocol clinical trials
How each study uses IFL protocol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- FOLFIRI Protocol
- 4
Studies by the year they started
4 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 4
Massachusetts General Hospital (1) · University of Wisconsin, Madison (1) · AIO-Studien-gGmbH (1) · Peking University (1)
Often tested with
Tested in the same studies.
Nivolumab (1) · Trastuzumab (1) · Pertuzumab (1) · Irinotecan (1) · Bevacizumab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test IFL protocol, phase 3 first.
- Dec 2026Identification and Treatment Of Micrometastatic Disease in Stage III Colon CancerPhase 3 · Massachusetts General Hospital
Studies
Open first, then newest update. How each study uses IFL protocol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Identification and Treatment Of Micrometastatic Disease in Stage III Colon CancerActive, not recruitingPhase 3Massachusetts General HospitalNCT03803553Written as FOLFIRI Protocol
- Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRCActive, not recruitingPhase 2University of Wisconsin, MadisonNCT04587128Written as FOLFIRI Protocol
- A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential ChemotherapyTerminatedPhase 2AIO-Studien-gGmbHNCT03331640Written as FOLFIRI Protocol
- Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine CarcinomaStatus unknownPhase 2Peking UniversityNCT03168607Written as FOLFIRI Protocol
Given beside what is tested · 9 — IFL protocol is usual care or a partner of the new treatment
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisRecruitingPhase 1/2Neonc Technologies, Inc.NCT06047379Written as FOLFIRI Protocol
- Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver MetastasesNot yet recruitingPhase 2UNICANCERNCT07359456Written as FOLFIRI Protocol
- RP-6306 in Patients With Advanced CancerCompletedPhase 2Canadian Cancer Trials GroupNCT05605509Written as FOLFIRI Protocol
- A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid TumorsTerminatedPhase 1Biosplice Therapeutics, Inc.NCT05084859Written as FOLFIRI Protocol
- SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System MalignanciesTerminatedPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT05039944Written as FOLFIRI Protocol
- Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction AdenocarcinomaActive, not recruitingPhase 2Federation Francophone de Cancerologie DigestiveNCT03959293Written as FOLFIRI Protocol
- A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRIStatus unknownPhase 1/2Scandion Oncology A/SNCT04247256Written as FOLFIRI Protocol
- Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal CancerCompletedPhase 2Federation Francophone de Cancerologie DigestiveNCT02181556Written as FOLFIRI Protocol
- Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.Status unknownPhase 2Rabin Medical CenterNCT04003792Written as FOLFIRI Protocol
As the comparator · 1 — what is tested is compared with IFL protocol
Codes
What other systems call IFL protocol · ClinicalTrials.gg INT004605
- MeSH (NLM) C480833IFL protocolOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C480833 | IFL protocol | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.